SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-17-024204
Filing Date
2017-04-18
Accepted
2017-04-18 17:03:43
Documents
7
Period of Report
2017-04-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a17-11472_18k.htm 8-K 51854
2 EX-2.1 a17-11472_1ex2d1.htm EX-2.1 810180
3 EX-2.2 a17-11472_1ex2d2.htm EX-2.2 58840
4 EX-2.3 a17-11472_1ex2d3.htm EX-2.3 56155
5 EX-2.4 a17-11472_1ex2d4.htm EX-2.4 53364
6 EX-2.5 a17-11472_1ex2d5.htm EX-2.5 58576
7 EX-99.1 a17-11472_1ex99d1.htm EX-99.1 28947
  Complete submission text file 0001104659-17-024204.txt   1119204
Mailing Address 3122 STERLING CIRCLE, SUITE 200 BOULDER CO 80301
Business Address 3122 STERLING CIRCLE, SUITE 200 BOULDER CO 80301 720-945-7700
Nivalis Therapeutics, Inc. (Filer) CIK: 0001626199 (see all company filings)

IRS No.: 208969493 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37449 | Film No.: 17767524
SIC: 2834 Pharmaceutical Preparations